Michael Gamalinda

902 citations
10 papers · 667 indexed · h-index 10
Topics
RNA modifications and cancer (10 papers)RNA and protein synthesis mechanisms (9 papers)Peptidase Inhibition and Analysis (5 papers)

In The Last Decade

Michael Gamalinda

10 papers receiving 666 citations

Peers

Michael Gamalinda
Comparison fields: 5 of 49
  • Molecular Biology 632
  • Oncology 107
  • Plant Science 64
  • Genetics 29
  • Cancer Research 26
Replace Bettina Bradatsch with:
Bettina Bradatsch Germany
Mélanie Rogier France
Daniela Strauß Germany
Martin Mašata Czechia
Sahra-Taylor Mullineux Canada
Weaam I Mohamed Switzerland
Kathleen M. Attwood Canada
Jaromı́ra Večeřová Czechia
Joonyoung Her United States
Malik Chaker-Margot United States
Michael Gamalinda relative to Bettina Bradatsch Germany Bettina Bradatsch's profile →
Citations per field
00.5×3.7×
Bettina Bradatsch · 1×
Citations per year

Countries citing papers authored by Michael Gamalinda

Since Specialization
Citations

This map shows the geographic impact of Michael Gamalinda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gamalinda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gamalinda more than expected).

Fields of papers citing papers by Michael Gamalinda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Gamalinda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gamalinda. The network helps show where Michael Gamalinda may publish in the future.

Co-authorship network of co-authors of Michael Gamalinda

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Gamalinda. A scholar is included among the top collaborators of Michael Gamalinda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Gamalinda. Michael Gamalinda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
#WorkIndexed citations
1 23
2 131
3 169
4 18
5 23
6 101
7 53
8 55
9 48
10 46

About Michael Gamalinda

Michael Gamalinda is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 10 papers that have together received 667 indexed citations. Recurring topics across this work include RNA modifications and cancer (10 papers), RNA and protein synthesis mechanisms (9 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Molecular Biology (632 citations), Structural Biology (9 citations) and Oncology (107 citations). Michael Gamalinda has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include John L. Woolford, Jelena Jakovljevic, Uli Ohmayer, Jesús de la Cruz, Ning Gao, Jason Talkish, Lawrence Lin, Yixiao Zhang, Chengying Ma and Hailey Brown. Their work appears in journals such as Nature, Nucleic Acids Research and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026